• We evaluated the long-term effects of indapamide, a nonthiazide diuretic, on blood pressure, glucoregulation, free insulin and C-peptide levels, and lipoprotein and apoprotein metabolism in 13 hypertensive diabetic patients for 24 weeks. Indapamide significantly reduced both systolic and diastolic blood pressure by 15% and 17%, respectively. Both mean fasting serum glucose and integrated glucose responses after oral glucose load (75 g) were significantly higher during indapamide therapy than at week 0. The mean fasting and stimulated C-peptide responses were significantly increased despite worsening glucose control. At the end of 24 weeks, mean glycosylated hemoglobin level had increased significantly. Indapamide caused a slight but insignificant rise in the total triglyceride, cholesterol, and low-density lipoprotein cholesterol levels, while the high-density lipoprotein cholesterol level decreased. In addition, the apoprotein A-1 concentrations remained unchanged while the apoprotein B-100 level decreased. Apart from hypokalemia (<3.5 mEq/L [<3.5 mmol/L]) in three patients that required oral potassium supplementation, biochemical changes were of no clinical consequence.
(Arch Intern Med 1986;146:1973-1977)
Osei K, Holland G, Falko JM. Indapamide: Effects on Apoprotein, Lipoprotein, and Glucoregulation in Ambulatory Diabetic Patients. Arch Intern Med. 1986;146(10):1973–1977. doi:10.1001/archinte.1986.00360220131023
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: